Join us as we look back on a decade of ERS Genomics, CRISPR and the IP that made it possible.

Over the past 10 years, CRISPR/Cas9 has moved from breakthrough discovery to a foundational platform for modern biology. In parallel, ERS Genomics has grown into the global leader in CRISPR/Cas9 licensing, helping more than 155 organisations worldwide.

In this special 10 year retrospective, we explore how access to the foundational CVC patent portfolio has supported innovators across biopharma, life science tools, agriculture, synthetic biology, and industrial biotech.